Zomedica Corp. (NYSE AMERICAN: ZOM) Stock Information | RedChip


 Research Profile  Company Website

Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $118.0 million cash and cash equivalents as of September 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions. The Company’s portfolio includes innovative products that emphasize both patient and practice health, including:


  • TRUFORMA® - In-clinic diagnostics with canine, feline, and equine assays
  • TRUVIEW® - Innovative digital imaging technologies
  • VetGuardian® - Wireless remote monitoring of vital signs

Therapeutic Devices:

  • PulseVet® - Shock wave therapy in equine and small animal market
  • Assisi® tPEMF® - Targeted pulsed electromagnetic field therapy

Zomedica’s mission is to achieve the five pillars: Improving the quality of care for the pet, the satisfaction of the pet parent, and veterinarian workflow, cash flow, and profitability.

Investor Presentation

Investor Presentation

Zomedica’s rapidly increasing revenues and attractive gross margins offer a clear pathway to profitability. Successful acquisitions and collaborations provide a blueprint for continued organic growth and product expansion. With a product line-up designed to address the needs of both companion animals and the veterinarians they rely upon and an animal health market that continues to exponentially grow, Zomedica finds itself primed to capitalize on a substantial amount of market opportunities. With a decreasing operating cash burn, a strong balance sheet (incl. $118.0 million in liquidity with no debt), and profitability on the horizon, Zomedica will continue to grow organically and opportunistically through acquisition, positioning itself as a very compelling opportunity for investors.

  • Substantial growth
    • 2022 revenue of $18.9 million, up 361% from 2021
    • Q3 YTD 2023 revenue of $17.8 million, up 39% from first nine months of 2022
    • Margins of ~70%
  • Solid financial position
    • Liquidity of $118.0 million as of September 30, 2023
    • Quarterly operating burn of less than ~$3 million
    • No debt
  • Growing portfolio
    • Sales for TRUFORMA and PulseVet (both launched in 2021) up 16% YoY
    • Sales of Assisi (2022), VetGuardian (2023) and TRUVIEW (2023) are contributing $4.2 million in sales through Q3 2023
  • Growing markets
    • Animal health market estimated to reach $88.6 billion by 2028
    • Companion animal diagnostic market forecasted to reach $12.6 billion by 2036
    • Product portfolio represents a $2.5 billion annual market opportunity in US alone
    • 23 million pets added during pandemic

Company Videos

*By entering your information you agree to our privacy policy.